MétaCan
Menu
← Back to cohort
Record W4416139954 · doi:10.1093/neuonc/noaf201.1653

SURG-101. A pilot study of laser interstitial thermal therapy (LITT) followed by hypofractionated radiation therapy (hypoRT) for patients with recurrent gliomas

2025· article· en· W4416139954 on OpenAlexaff
Mark V. Mishra, Ahmad Ozair, Haroon Ahmad, Alexander Ksendzovsky, Lily C Pham, Young Kwok, Sarah McAvoy, Nima Sharifai, Heather M. Ames, Megan Camara, C. Eggleston, William F. Regine, Graeme F. Woodworth

Bibliographic record

VenueNeuro-Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsMcGill UniversityMontreal Neurological Institute and Hospital
Fundersnot available
KeywordsRegimenRadiation therapyClinical endpointSalvage therapyGliomaBiopsyRadiography

Abstract

fetched live from OpenAlex

Abstract BACKGROUND Patients with recurrent glioma have substantial morbidity and mortality. Salvage radiotherapy (RT) is commonly utilized for recurrent gliomas, with salvage hypofractionation (hypoRT) offering acceptable safety and accelerated schedule. Laser interstitial thermal therapy (LITT) feasibly allows for tumor thermoablation, with particular utility in recurrent tumors and symptomatic radiation necrosis. Given that LITT can be provided pre-RT, offers concurrent opportunity for stereotactic biopsy (with tissue-based diagnosis of recurrence versus radionecrosis, preventing the latter patient from receiving further RT), and could thermally sensitize tissue to subsequent RT, therefore, a rationale exists for combining LITT followed by hypoRT (LITT+hypoRT) for recurrent glioma. METHODS A pre-registered (NCT04181684), single-arm, pilot study was conducted for adult patients, aged ≥18 years, with WHO 2016 Grade II-IV glioma with radiographic recurrence, who had received once-prior RT (≥8-week interval, but no more than 1 irradiation); KPS ≥60 at enrolment; and were LITT candidates. Following MR-guided LITT, patients received hypoRT (35Gy/10 fractions, per NRG/RTOG-1205) only after LITT-biopsy confirmed recurrence. HypoRT simulation was performed within 10 days of LITT, and treatment delivered using either photon (IMRT) or proton beam, as appropriate. Primary endpoint was safety, hypothesized that <40% of patients completing full LITT+hypoRT regimen will have Grade ≥3 neurologic treatment-related toxicity (CTCAEv5.0). Secondary endpoints were median progression-free survival (PFS), median overall survival (OS), 6-month PFS, 1-year OS, 2-year OS, overall response (RANO), and quality of life. RESULTS Trial enrolment began in 03/2020 and concluded in 06/2025, with 24 patients having completed protocol-defined LITT+hypoRT regimen so far (one additional patient undergoing further treatments and expected to finish protocol shortly to complete final evaluable cohort). Median age was 62 years (range 29-75), with all non-Hispanic ethnicity patients. Median KPS was 80 (range 60-100). Median LITT-associated hospital length-of-stay was 2 days. Median hypoRT delivery time was 13 days. Pending completion of protocol-defined treatments, final endpoint data will be presented at conference. CONCLUSIONS LITT+hypoRT could be feasible approach for recurrent glioma.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.306
Teacher spread0.283 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology→Same topicGlioma Diagnosis and Treatment→French-language works237,207→